PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.

CONCLUSIONS: The results indicate that pioglitazone, a PPARγ agonist, has a beneficial protective effect against melanoma via interfering with the TLR4-dependent signaling pathways. PMID: 31509504 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research